Muscle B mode ultrasound and shear-wave elastography in idiopathic inflammatory myopathies (SWIM): criterion validation against MRI and muscle biopsy findings in an incident patient cohort

Shereen Paramalingam1,2*, Merrilee Needham1,3,4,8, Sarah Harris5,6, Susan O’Hanlon7, Frank Mastaglia8 and Helen Keen2

Abstract

Background: B mode ultrasound (US) and shear wave elastography (SWE) are easily accessible imaging tools for idiopathic inflammatory myopathies (IIM) but require further validation against standard diagnostic procedures such as MRI and muscle biopsy.

Methods: In this prospective cross-sectional study we compared US findings to MRI and muscle biopsy findings in a group of 18 patients (11 F, 7 M) with active IIM (dermatomyositis 6, necrotising autoimmune myopathy 7, inclusion body myositis 4, overlap myositis 1) who had one or both procedures on the same muscle. US domains (echogenicity, fascial thickness, muscle bulk, shear wave speed and power doppler) in the deltoid and vastus lateralis were compared to MRI domains (muscle oedema, fatty infiltration/atrophy) and muscle biopsy findings (lymphocytic inflammation, myonecrosis, atrophy and fibro-fatty infiltration). A composite index score (1–4) was also used as an arbitrary indicator of overall muscle pathology in biopsies.

Results: Increased echogenicity correlated with the presence of fatty infiltration/atrophy on MRI ($p = 0.047$) in the vastus lateralis, and showed a non-significant association with muscle inflammation, myonecrosis, fibrosis and fatty infiltration/atrophy ($p > 0.333$). Severe echogenicity also had a non-significant association with higher composite biopsy index score in the vastus lateralis ($p = 0.380$). SWS and US measures of fascial thickness and muscle bulk showed poor discrimination in differentiating between pathologies on MRI or muscle biopsy. Power Doppler measures of vascularity correlated poorly with the presence of oedema on MRI, or with inflammation or fatty infiltration on biopsy. Overall, US was sensitive in detecting the presence of muscle pathology shown on MRI (67–100%) but showed poorer specificity (13–100%). Increased echogenicity showed good sensitivity when detecting muscle pathology (100%) but lacked specificity in differentiating muscle pathologies (0%). Most study participants rated US as the preferred imaging modality.

© The Author(s) 2022, corrected publication 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Conclusions: Our findings show that US, in particular muscle echogenicity, has a high sensitivity, but low specificity, for detecting muscle pathology in IIM. Traditional visual grading scores are not IIM-specific and require further modification and validation. Future studies should continue to focus on developing a feasible scoring system, which is reliable and allows translation to clinical practice.

Keywords: Shear wave elastography, B mode Ultrasound, Idiopathic inflammatory myopathies, Imaging, Myositis

Introduction

Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of rare autoimmune diseases that carry a significant morbidity from musculoskeletal complications, as well as potentially serious systemic manifestations in some cases [1]. Early diagnosis is important to allow prompt intervention and improve outcomes.

The gold standard test for the diagnosis of IIM currently remains the muscle biopsy. Varying combinations of muscle inflammation, myofibre necrosis, degeneration, atrophy, and fatty infiltration/fibrosis are typically reported biopsy findings in the IIMs [2, 3] Less invasive methods to assess muscle integrity, such as imaging modalities do have some clinical utility, and magnetic resonance imaging (MRI) is currently regarded as the most sensitive screening modality to identify the presence of muscle pathology in the IIMs [4]. Muscle oedema, atrophy and fatty infiltration are MRI features that are considered to be indicative of muscle inflammation and damage [5].

Clinical led point-of-care ultrasound (US) has rapidly progressed to become a useful imaging outcome tool for various rheumatological conditions [6, 7]. However, there have been relatively few studies of muscle ultrasound in inflammatory muscle diseases, and the role of ultrasound in the diagnosis and monitoring of different varieties of IIM has still not been clearly defined. Moreover, there is a lack of studies that have attempted to compare ultrasound findings with MRI and muscle biopsy changes in different forms of myositis or to evaluate the changes in different ultrasound domains over the course of these diseases, and in response to treatment. Shear wave elastography (SWE), a relatively novel form of US that provides a measure of changes in muscle stiffness, has recently been introduced as a potential complementary tool to traditional B mode US when investigating the limb muscles but requires further investigation in myositis [8, 9]. The validation of US against other diagnostic modalities such as MRI and muscle histopathology in IIM is an essential requirement in facilitating translation of its use into clinical practice.

In this study, we have attempted to correlate changes in muscle ultrasound domains with MRI and muscle biopsy findings in patients with different forms of IIM. The primary objective of the study was to assess the construct and criterion validity of different muscle US domains (viz. echogenicity, muscle bulk, shear wave speed (SWS and power Doppler) against (i) MRI findings of muscle oedema, fatty infiltration/atrophy; and/or (ii) muscle biopsy findings (viz. lymphocytic inflammation, myonecrosis, atrophy, interstitial fibrosis and fatty infiltration) in a mixed group of IIM patients. A secondary objective of the study was to assess intra-observer reliability testing and patient satisfaction with US compared with MRI.

Methods and methodology

Participants

Twenty-five patients with a new diagnosis of IIM were recruited sequentially from the rheumatology clinics at Fiona Stanley Hospital and the myositis clinic at the Institute for Immunology and Infectious Diseases at Murdoch University between June 2019 and May 2021. All participants gave written informed consent.

Recruitment

Human Research Ethics Committee (HREC) approvals were granted by the South Metropolitan Health Service (HREC) (RGS0000003714) and reciprocal ethics were obtained from Murdoch University (2018/237). Patients were required to be ≥18 years old, able and willing to provide written informed consent and attend a clinical study visit at a neuromuscular centre. IIM patients were eligible for the study if they satisfied the 2017 European League Against Rheumatism (EULAR) classification of IIM [10] and/or 188th Neuromuscular Centre (ENMC) diagnostic criteria for IBM [11] and/or ENMC 2004 diagnostic criteria for immune-mediated Necrotising Autoimmune Myopathy (NAM) [12]. Patients were recruited within three months of diagnosis to enable comparison with other investigations.

Clinical assessment

All participants (n = 25) completed patient-reported questionnaires, including a health assessment questionnaire (HAQ), a partially validated tool looking at the functional disability index [13]. A higher index indicates higher functional disability or disease activity. All patients (n = 25) had a clinical examination with manual muscle testing (MMT) in 26 muscle groups [14]. The MMT 26 is a partially validated tool with a total score
of 260. The lower the score, the weaker the patient. All patients \( n = 25 \) had a serum creatine kinase (CK) assay as well as other routine biochemical and haematological investigations [15]. As part of their diagnostic workup, 16 patients had MRI of the proximal upper and lower limb muscles, and 13 had a muscle biopsy, which was used as comparators for the US findings (Figs. 1 and 2). The 7 patients without muscle biopsies were from the IBM and anti-HMGCR associated NAM groups, the diagnosis in these cases being based on the clinical phenotype and serological findings. All patients were asked to fill in a patient satisfaction survey for US and MRI.

**Imaging/anatomical landmarks**
US and SWE were performed by the same clinician (SP), who had 6 months of supervised training in shear wave elastography (SWE) and 5 years of B mode US experience. In all patients, US and SWE were routinely performed on the left deltoid and right vastus lateralis muscles. The deltoid and vastus lateralis muscles are known to be commonly affected in the IIMs and are the most frequently targeted with MRI and muscle biopsy [16].

**B mode ultrasound technique and protocol**
The ultrasound studies were performed in a controlled temperature air-conditioned room. Patients rested for a period of ~15 min before the procedure and had been instructed not to perform recreational exercise on the day of the procedure or the preceding day.

B mode US was done using a Siemens machine with 750PRF and 14 MHz. The probe position for imaging the deltoid was at a point one-third of the distance from the acromion to the lateral epicondyle. The arm was flexed in a 90° position held at rest on a pillow. The probe position for imaging the vastus lateralis was at a point one-quarter of the distance from the anterior superior iliac spine (ASIS) to the superior border of the patella [17]. The vastus lateralis was scanned with the knee extended on the bed. Both transverse and longitudinal views of the deltoid and vastus lateralis were obtained. Two images were obtained in each plane and scored.

The B mode features scored were:
(1) Fascial thickness was measured in transverse position using the calliper function, with a total of 6 readings in 2 frames with the callipers placed 0.25 cm apart at the most homogenous area of the muscle and averaged [15]. Fascia was defined as the aggregate of connective tissue enveloping the muscle [18] (Additional file 2: Fig. S2).

(2) Muscle bulk was measured at the broadest point of the muscle belly, from the deep peripheral fascia to the deep intramuscular fascia using the calliper function [15] (Additional file 2: Fig. S2).

(3) Echogenicity, using the Heckmatt visual grading scale (ordinal grade of 1–4) [19], which is a 4 point semi-quantitative scale: 1 = normal, 2 = echogenicity with preservation of bone echo, 3 = echogenicity with partial loss of bone echo and 4 = echogenicity with complete loss of bone echo [19]. A modified version was used where the image was studied in both transverse and longitudinal planes. Higher grade scores correlate with higher echogenicity. For statistical analysis, echogenicity was recorded dichotomously as present/absent, and also graded: normal (grade 1), mild (grade 2) and severe (grade 3–4).

**Power Doppler (PD)**

PD was assessed at rest in both the transverse and longitudinal planes. The PD signal was graded as: ‘normal’, ‘mild’, ‘severe’ (Additional file 5: Table S3).

**Shear wave elastography**

This was initially performed using the transverse probe position, but during the course of the study the longitudinal plane was also included in view of some studies showing increased reliability with this orientation [20]. SWE was performed using the same Siemens US machine with dual B mode and shear wave capabilities. Minimal contact probe pressure was ensured. Two images with 3 readings in each image were taken using an ROI of 10 mm². The average reading was recorded. This was done for both the deltoid and vastus lateralis.

**MRI**

T1 and STIR images on MRI were used to score oedema and fatty infiltration/atrophy. Muscle oedema reported on MRI is presumed to represent inflammation, while fatty infiltration/atrophy are considered to reflect myofibre loss and damage in the muscle [5]. Muscle oedema and fatty infiltration/atrophy were scored dichotomously as present/absent.

**Muscle biopsy**

Both light and electron microscopy were performed on the muscle biopsy samples. The major pathological features reported on muscle biopsy comprised: (i) interstitial lymphocytic inflammatory infiltrates; (ii) myofibrocyte necrosis/regeneration; (iii) interstitial fibrosis; and (iv) fatty infiltration/atrophy, collectively being indicators of the extent, severity and chronicity of damage in individual muscles. In addition, to enable comparisons between ultrasound findings and overall muscle pathology, an arbitrary composite pathology index score (1–4) was calculated for each biopsy based on how many of the above four pathology domains were present in individual biopsies.

**Patient satisfaction survey**

All participants were asked to fill in a patient satisfaction survey and were required to answer seven questions on their level of satisfaction with US and MRI, respectively. The overall satisfaction with US and MRI were rated separately on a 5-point Likert Scale (1-very good, 2-good, 3-barely acceptable, 4-poor and 5-very poor). An additional question was tabulated regarding preference for imaging modality, where there were 3 options (US, MRI or either) available.

**Intra-observer reliability**

The echogenicity and power Doppler US domains in 15 of the participants were re-assessed by the first author for intra-observer reliability at an interval of 8 months after recruitment of the last patient.

**Statistical analysis**

Mean (M), standard deviation (SD), median (Mdn) and interquartile ranges (IQR) were used for continuous data. Categorical data were presented using frequency and percent (%). For statistical analysis, echogenicity was considered increased when it showed a grade of 2–4 according to the Heckmatt visual grading scale. PD was considered present when it showed a grade of 1–4 according to the Heckmatt visual grading scale. PD was considered present when it showed a grade of 1–4. The sensitivity and specificity of US were estimated using MRI and muscle biopsy as the gold-standard comparators. Differences in the categorical variables were explored using Fischer’s exact test (echogenicity and PD) or a Paired-Samples t-test (or non-parametric equivalent) (for fascial thickness, muscle bulk and SWS) or reported descriptively. The Mann Whitney U test was used for the comparison between ultrasound and MRI domains. Intra-observer reliability was reported with a kappa value. Patient preference for US was described as the overall percentage.
Results

Descriptive demographic data

Following an initial screening, 20 of the 25 patients recruited were considered eligible for inclusion in the study. The 5 patients excluded were initially thought to have a clinical diagnosis of IBM, but after investigation, they did not fulfill the diagnostic criteria for the disease. The median age was 64.0 (IQR: 54.0–70.0) with more females (n = 11, 55.0%) than males (n = 9, 45.0%). Six (30%) participants had a diagnosis of DM, 7 (35%) of NAM, 6 (30%) of IBM, and one of OM (5%). The mean serum CK level at baseline was 4518 U/L (SD = 6036.04).

The mean MMT score in the deltoid was 9 (SD = 2.69) and in the vastus lateralis was 7 (SD = 2.77). Eleven participants (55.0%) had both an MRI and muscle biopsy, five (25.0%) had only an MRI, 2 (10.0%) had only a muscle biopsy, and 2 (10.0%) had neither. The median time interval between US and MRI is 53 days (IQR: 15–109) and the median time interval between the US and muscle biopsy is 41 days (21–116). Of the 16 patients who had MRI, 12 had the vastus lateralis imaged, 2 had both the deltoid and vastus lateralis imaged, and 2 had the deltoid only. Of the 13 patients who had a biopsy, 12 had the vastus lateralis biopsied, and 1 had the deltoid biopsied. The two patients who did not have either MRI or muscle biopsy were elderly individuals with IBM who had a typical pattern of muscle weakness and other laboratory findings (serum CK, serology, electromyography) and their data (including US data) were included in the demographic analysis but not the comparative analysis. (Table 1) (Additional file 3: Table S1, Additional file 1: Fig. S1).

Changes observed with B mode ultrasound

In the deltoid, the median fascial thickness was 0.08 mm (IQR 0.700–0.900), median muscle bulk was 1.54 cm (IQR: 1.19–1.86), median SWS transverse 2.52 m/s (IQR 2.11–2.99), median SWS long 2.70 m/s (IQR: 2.46–2.93). Eleven (11/20, 55%) participants showed increased echogenicity and 11 (11/20, 55%) showed increased vascularity on PD.

In the vastus lateralis, the median fascial thickness was 0.15 (IQR: 0.70–0.90), median muscle bulk was 1.25 cm (IQR: 0.76–1.86), median SWS transverse 2.45 m/s (IQR 1.78–3.04) and median SWS long 2.44 m/s (IQR: 1.98–3.22). Eighteen (18/20, 90%) showed increased echogenicity and 11 (11/20, 55%) showed increased vascularity on PD.

Comparison between US domains and MRI findings

Median values for fascial thickness, muscle bulk and SWS on US were not associated with the presence of oedema, or other changes (e.g., fatty infiltration or atrophy) indicating muscle damage on MRI, in either the deltoid (p > 0.400) or vastus lateralis (p > 0.370). In the vastus lateralis, there was a non-significant association between increased muscle bulk on US and muscle oedema on MRI (p = 0.240), and reduced muscle bulk on US and fatty infiltration/atrophy on MRI (p = 0.223) (Additional file 4: Table S2). The grade of echogenicity on US did not reliably differentiate between the presence of inflammation or other features of muscle damage on MRI in the deltoid (p > 0.082). However, high-grade echogenicity with associated with fatty infiltration and atrophy in the vastus lateralis (p = 0.047). There was a poor association between PD signal intensity and the presence of oedema reported on MRI in both the deltoid and vastus lateralis (Additional file 5: Table S3).

Comparison between US domains and muscle biopsy findings

In the vastus lateralis, the median values for fascial thickness, muscle bulk and SWS did not differentiate between the presence or absence of inflammation, necrosis, fibrosis, or fatty infiltration/atrophy on muscle biopsy (p > 0.120) (Additional file 6: Table S4). Although not reaching statistical significance due to the low numbers, increased echogenicity on US was associated with the presence of inflammation (p = 1.000), necrosis (p = 1.000), fibrosis (p = 0.406) and fatty infiltration/atrophy (p = 0.333) in biopsies. Similarly, although not reaching statistical significance, it is interesting to note that higher grade echogenicity was associated with more pathologies on biopsy (p = 0.380). There was no association between vascularity on PD and the various pathologies on muscle biopsy (p > 0.318) (Additional file 7: Table S5).

As the deltoid muscle was biopsied in only one case, we could not adequately compare the continuous and categorical variables in this muscle.

Sensitivity and specificity of US

Data are presented in Table 2. When using increased echogenicity as the leading US domain in the deltoid, the US had a high sensitivity rate at detecting the presence of muscle pathology on MRI (67–100%) and showed good specificity (75–100%). As only one deltoid was biopsied, the data was omitted. In the vastus lateralis, US was highly sensitive in detecting muscle pathology on MRI (83–90%) and on muscle biopsy (100%) but lacked specificity (13–25%) on MRI and (0%) on muscle biopsy.

Intra-observer reliability

For echogenicity, the intra-observer reliability reported a kappa of 0.589 (moderate agreement) in the deltoid and a kappa of 0.881 (substantial agreement) in the vastus
| Participant | Symptom duration | Time since diagnosis | Age | Sex | Diagnosis | Myositis specific antibodies | CK level | MMT Deltoid/10 | MMT Vastus Lateralis/10 | Medications at the time of US | Echo deltoid (1–4) | Echo vastus lateralis (1–4) | PD Deltoid (0–4) | PD vastus lateralis (0–4) | MRI deltoid | MRI vastus lateralis | Muscle biopsy deltoid | Muscle biopsy vastus lateralis |
|-------------|-----------------|---------------------|-----|-----|-----------|-------------------------------|----------|----------------|-----------------------|----------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|-----------------|------------------------|
| 1           | < 1 yr          | < 1 mth             | 30  | F   | NAM       | Seronegative                  | 9,350    | 9              | 9                     | Prednisolone, methotrexate | 1              | 2                      | 0              | 0                      | Oedema N/A     | N/A                    | N/A              | N/A                    |
| 2           | < 1 mth         | < 1 mth             | 54  | F   | NAM       | Anti-HMGCR                | 9,390    | 8              | 9                     | Prednisolone, methotrexate | 2              | 2                      | 0              | 0                      | Oedema N/A     | N/A                    | N/A              | N/A                    |
| 3           | < 6 mth         | < 1 mth             | 66  | F   | NAM       | Seronegative                  | 10,600   | 9              | 10                    | Nil                        | 2              | 3                      | 0              | 0                      | N/A            | Fatty infiltration    | N/A              | Atrophy               |
| 4           | < 1 yr          | < 6 mth             | 79  | F   | DM        | Anti-OJ, Anti-NXP2           | 553      | 9              | 9                     | Nil                        | 1              | 2                      | 0              | 1                      | N/A            | Atrophy, fatty infiltration | N/A              | N/A                    |
| 5           | < 5 yrs         | < 1 mth             | 70  | F   | BM        | Seronegative                  | N/A      | 9              | 9                     | Nil                        | 2              | 3                      | 0              | 1                      | N/A            | Fatty infiltration     | N/A              | N/A                    |
| 6           | ≥ 5 yrs         | < 1 mth             | 60  | F   | OM        | Anti-Ro-52, Anti-NXP2         | N/A      | 10             | 8                     | Nil                        | 2              | 3                      | 2              | 0                      | Oedema N/A     | Inflammation, fibrosis, fatty infiltration | N/A              | N/A                    |
| 7           | < 5 yrs         | < 1 mth             | 74  | M   | IBM       | Seronegative                  | 359      | 10             | N/A                   | Nil                        | 2              | 0                      | 0              | 1                      | N/A            | N/A                    | N/A              | N/A                    |
| 8           | < 1 mth         | < 1 mth             | 20  | M   | DM        | Anti-Mi2a                    | 14,900   | 1              | 3                     | Prednisolone               | 1              | 2                      | 3              | 0                      | Oedema N/A     | Inflammation, fibrosis, fatty infiltration | N/A              | N/A                    |
| 9           | ≥ 5 yrs         | < 1 yr              | 60  | M   | DM        | Anti-Ro-52, Anti-NXP2         | 6410     | 1              | 1                     | Prednisolone, mycophenolate | 1              | 1                      | 1              | 2                      | Oedema, fatty infiltration N/A | N/A                    | Inflammation, fibrosis, fatty infiltration | N/A              | N/A                    |
| 10          | < 5 yrs         | < 6 mths            | 70  | M   | IBM       | Seronegative                  | N/A      | 10             | 8                     | Nil                        | 1              | 4                      | 0              | 0                      | N/A            | N/A                    | N/A              | N/A                    |
| 11          | < 5 yrs         | < 1 mth             | 63  | M   | IBM       | Anti-CN1A                    | 261      | 10             | 2                     | Nil                        | 1              | 3                      | 2              | 0                      | N/A            | N/A                    | N/A              | N/A                    |
Table 1 (continued)

| Participant | Symptom duration | Time since diagnosis | Age  | Sex | Diagnosis | Myositis specific antibodies | CK level | MMT Deltoid/10 | MMT Vastus Lateralis/10 | Medications at the time of US | Echo deltoit (1–4) | Echo vastus lateralis (1–4) | PD Deltoit (0–4) | PD Vastus lateralis (0–4) | MRI deltoit | MRI vastus lateralis | Muscle biopsy deltoit | Muscle biopsy vastus lateralis |
|-------------|-----------------|----------------------|------|-----|-----------|------------------------------|----------|-----------------|--------------------------|------------------------------|------------------|--------------------------|-----------------|------------------------|----------------|------------------|-----------------|-------------------------|
| 12          | <1 yr           | <6 mths              | 65   | M   | IBM       | Seronegative                 | 1070     | 10              | 9            | Nil                           | 2                 | 3                        | 0               | 0                      | N/A          | Oedema, fatty infiltration | N/A              | Inflammation, fibrosis, fatty infiltration |
| 13          | <1 yr           | <1 mth               | 26   | F   | DM       | Anti-NXP2                    | 287      | 8               | 9            | Prednisolone, methotrexate | 1                 | 2                        | 1               | 0                      | N/A          | Oedema                | N/A              | Inflammation          |
| 14          | ≥5 yrs          | <1 mth               | 69   | M   | NAM      | Anti-SRP                     | 436      | 10              | 8            | Nil                           | 1                 | 2                        | 1               | 2                      | N/A          | N/A                   | N/A              | N/A                    |
| 15          | ≥5 yrs          | <6 mth               | 70   | M   | IBM       | Seronegative                 | 69       | 10              | 10           | Nil                          | 1                 | 1                        | 1               | 1                      | N/A          | Normal                | Normal            | N/A                    |
| 16          | <1 yr           | <1 mth               | 65   | F   | NAM      | Seronegative                 | 11       | 10              | 9            | Prednisolone, mycophenolate | 3                 | 3                        | 0               | 0                      | N/A          | Oedema, fatty infiltration | N/A              | Inflammation, fatty infiltration |
| 17          | <1 yr           | <1 mth               | 33   | F   | NAM      | Seronegative                 | 4010     | 9               | 7            | Prednisolone, hydroxychloroquine, mycophenolate | 3                 | 3                        | 0               | 1                      | N/A          | Oedema, atrophy          | N/A              | Inflammation, fibrosis, fatty infiltration |
| 18          | <1 yr–<5 yrs    | <6 mths              | 54   | F   | DM       | Seronegative                 | 19       | 10              | 5            | Mycophenolate, prednisolone, IVG | 2                 | 2                        | 0               | 0                      | N/A          | Oedema                | N/A              | Fatty infiltration and fibrosis |
| 19          | <6 mths         | <6 mths              | 61   | M   | NAM      | Anti-HMGCR                   | 19,000   | 8               | 5            | Prednisolone, methotrexate | 1                 | 3                        | 0               | 0                      | Oedema      | Oedema               | N/A              | Inflammation, fibrosis, fatty infiltration |
| 20          | ≥5 yrs          | <1 mth               | 79   | F   | DM       | Anti-SAE                     | 87       | 9               | 7            | Nil                           | 3                 | 3                        | 1               | 1                      | N/A          | Atrophy, fatty infiltration | N/A              | Inflammation, fibrosis, fatty infiltration |

Median/SD – – 64/17 – – – 553/3 10 8 – – – 1/1 3/1 0/1 0/1 – – – –

NAM: Necrotising autoimmune myopathy, DM: dermatomyositis, IBM: inclusion body myositis, OM: overlap myositis, CK: creatinine kinase, MMT: manual muscle testing, PD: power Doppler, MRI: magnetic resonance imaging, mths: months, yrs: years, N/A: not available. SD: standard deviation, Echo; echogenicity
For PD, the intra-observer reliability reported a kappa of 0.714 (important agreement) in the deltoid and a kappa of 0.746 (significant deal) in the vastus lateralis.

Participant satisfaction sub-analysis
Eighteen of the 20 participants (90%) responded to the participation satisfaction questionnaire. Seventeen participants (94.4%) overall satisfaction with ultrasound and MRI as very good and one (6%) as good. Eleven participants (11/15, 73.3%) rated the US as the preferred imaging modality, 4 (4/15, 26.7%) liked either (US or MRI), with none (0/15, 0%) choosing MRI.

Discussion
Before B-mode ultrasound can be accepted as a non-invasive diagnostic procedure of choice for IIMs, changes in individual US domains must be validated against current gold standard diagnostic techniques such as MRI and histopathological findings in the muscle examined. Our study has attempted to do this in a mixed clinic cohort of IIM patients, which included all the primary forms of autoimmune myositis (dermatomyositis, overlap myositis, necrotising autoimmune myositis and inclusion body myositis), except polymyositis, whose existence as a separate entity is controversial and rarely diagnosed [1].

The primary objective was to compare individual ultrasound domains against features of inflammation and muscle damage as shown by MRI and muscle biopsy. This is the first study of this type in which a range of US domains has been compared against specific pathological features on muscle biopsy and a composite score reflecting the overall severity of pathological changes in the biopsy.

The median age of the participants in the study was 64 years, which is reflective of the inclusion of specific IIM subtypes such as IBM, which usually presents over the period of 50 [21]. Participants all had mild to moderate degrees of muscle weakness, and all but two had varying degrees of serum CK elevation, as shown in Table 1.

Most participants were entered into the study at the initial diagnostic workup, which included either an MRI, muscle biopsy or both investigations. Still, two elderly patients with typical clinical features (history, examination, EMG and CK levels) of sporadic IBM did not have an MRI or muscle biopsy. Myositis-specific autoantibodies were present in 10/20 (50%) participants and helped classify the myositis subtype in these cases [22]. As the classification of IIM continues to evolve, non-invasive investigations such as serological markers are now assuming a more important role in diagnosis. They may avoid the need for muscle biopsy in some cases [22].

Although our findings indicated a correlation between increased echogenicity on US and fatty infiltration and atrophy on MRI, the degree of echogenicity did not reliably differentiate between inflammation and other features of muscle damage, which brings into question the US grading scale used. The Heckmatt grading scale [19], or modified versions of it, are predominately used in neuromuscular ultrasound studies, despite being quite dated [23], and do not consider echogenicity as a feature of inflammation. Since then, the Siena group have proposed a new greyscale and power doppler scoring system for IIMs [24], which predominantly uses hypoechogenicity as an indicator of oedema and hyperechogenicity as an indicator of muscle damage. However, as this was a construct validity study, it was not designed to interrogate the criterion validity of this newly proposed grading scale. This grading scale was not included in the present study. Our study commenced before the new proposed Siena grading criteria were released. Different reference muscles were used in the two studies (e.g. rectus femoris in the Siena study and vastus lateralis in the present study). It is also unclear whether the vastus intermedius, as proposed by the Siena group, can be used as a normal healthy comparator to a diseased muscle, as the vastus intermedius may also be involved in IIM. Although not reaching statistical significance, our finding of

|                      | MRI muscle oedema (%) | MRI atrophy/fatty infiltration (%) | Bx-inflammation (%) | Bx-necrosis (%) | Bx-fibrosis (%) | Bx-atrophy/fatty infiltration (%) |
|----------------------|-----------------------|------------------------------------|---------------------|----------------|----------------|-----------------------------------|
| Deltoid sensitivity   | 67                    | 100                                | 83                  | 83             | 100            | 100                               |
| Deltoid specificity   | 100                   | 75                                 | 0                   | 0              | 0              | 0                                 |
| Deltoid PPV           | 100                   | 50                                 | 83                  | 83             | 67             | 92                                |
| Deltoid NPV           | 50                    | 100                                | 0                   | 0              | 0              | 0                                 |
| Vastus lateralis sensitivity | 90                  | 83                                 | 100                 | 100            | 100            | 100                               |
| Vastus lateralis specificity  | 25                 | 13                                 | 0                   | 0              | 0              | 0                                 |
| Vastus lateralis PPV  | 75                    | 42                                 | 83                  | 83             | 67             | 92                                |
| Vastus lateralis NPV  | 50                    | 50                                 | 0                   | 0              | 0              | 0                                 |

Bx: Muscle biopsy; PPV: positive predictive value; NPV: negative predictive value; MRI: magnetic resonance imaging
increased muscle bulk on the US in muscles showing oedema on MRI, and conversely of reduced muscle bulk when MRI showed changes of chronic muscle damage (i.e., fibrosis and fatty infiltration), are intuitively concordant and also align with previous literature [18].

Because of our small sample sizes and heterogeneity of biopsy findings in participants with different forms of IIM, the comparison of US findings with histopathological features placed more emphasis on descriptive observations. Nevertheless, a non-significant association between high echogenicity and histological features of inflammation, myonecrosis and fatty infiltration/atrophy was observed in the vastus lateralis. This is interesting, as previous reports have suggested that hypoehogenicity is associated with the presence of oedema on MRI, particularly in early, more active forms of myositis [19]. Our findings indicate that from a pathological standpoint, these changes are all combined to varying degrees in individual patients depending on the disease duration, IIM subtype and activity of the disease at the time of the investigations. A possible explanation for higher echogenicity in our study is the inclusion of patients with more chronic forms of IIM, such as sporadic IBM. Apart from increased echogenicity, other US domains such as fascial thickness, muscle bulk, and SWS did not correlate with muscle histological changes.

Increased power Doppler signal, indicative of increased vascularity, has previously been associated with muscle oedema and early, more active myositis [17, 19]. However, in the more chronic IIM cohort, we found a poor correlation between PD signal and oedema on MRI or inflammation and fatty infiltration on muscle biopsy. Increased vascularity is assumed to occur in the presence of acute inflammation, correlating with disease activity [24, 25]. The disparity between our PD findings and some previous studies is likely to be due to differences in the types of IIM cases included in the study and disease activity and treatment effects at the time of the investigation. Our findings with PD were similar to those in our previous preliminary study, which suggested that the PD score was of limited value in differentiating between pathological and normal muscle and drew attention to the possible confounding effects of exercise, temperature and hyperdynamic states on the PD signal [9].

Limitations
There are several limitations to the present study. Firstly, the small sample size and heterogeneity of the IIM cohort are potential limitations that could affect the significance and generalisability of the findings. Due to the low prevalence of IIMs, future studies will need to consider multisite data collection or extend the data collection period to overcome this issue. Secondly, ultrasound remains operator-dependant, and the lack of standardised protocols and consensus agreements on what constitutes features of inflammation and muscle damage may influence the reliability of the findings. Thirdly, the MRI and muscle biopsies were not all prospective and coincident in time. Biopsies were not MRI-guided, which may have reduced the strength of some of the associations found between the imaging and pathology domains. The MRI was scored dichotomously in this study, but other ways to achieve pathology on MRI also warrant further investigation.
Acknowledgements
Dr. Paramalingam is the recipient of the Byron Kakulas Top-Up Scholarship and Patricia Kallis Scholarship. Sarah Harris was supported by the WAHTN Biostatistics Fellowship. The authors acknowledge the valuable input of Dr. Jason Dyke for reporting and advice on the interpretation of the muscle biopsies. We also thank Kelly Beer, Deborah Robertson, Daniel Lightowler and Karen Martin for helping to co-ordinate the research clinics and patient recruitment.

Author contributions
SP-conceptualisation, principal investigator of the study, data analysis, writing of the manuscript, preparation of tables and figures. MN-supervisor, associate investigator of the study, editing of the manuscript, SH-statistician, data analysis, editing of the manuscript. SOH-Radiologist, reporting of MRI, editing of the manuscript. FM-supervisor, critical review and editing of manuscript and illustrations. HK-conceptualisation, supervisor, associate investigator of the study, editing of manuscripts. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
All data and materials are available in this publication in the Additional files 3–7.

Declarations
Ethics approval and consent to participate
All authors confirm that this study was performed by good clinical practice (GCP) guidelines. The licensing institution approving the study is Fiona Stanley Hospital (as part of the South Metropolitan Health ethics committee), and reciprocal approvals were obtained through Murdoch University and the Peron Institute of Neurological Science. All methods were carried out according to relevant guidelines and regulations. The South Metropolitan Health ethics committee approved all study protocols. Written informed consent was obtained from all participants.

Consent for publication
Not applicable.

Competing interests
All authors declare that they have no competing interests.

Author details
1 University of Notre Dame Australia, Fremantle, WA, Australia. 2 Department of Rheumatology, Fiona Stanley Hospital, 11 Robin Warren Dr, Murdoch, WA 6150, Australia. 3 Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, WA, Australia. 4 Department of Neurology, Fiona Stanley Hospital, Murdoch, WA, Australia. 5 Institute for Health Research, Notre Dame Australia, Fremantle, WA, Australia. 6 Western Australian Health Translation Network (WAHTN), Bentley, WA, Australia. 7 Department of Radiology, Fiona Stanley Hospital, Murdoch, WA, Australia. 8 Present Address: Peron Institute for Neurological and Translational Science, University of Western Australia, Crawley, Australia.

Received: 23 January 2022   Accepted: 16 May 2022

References
1. Lundberg IE, Fujimoto M, Vencovský J, Aggarwal R, Holmqvist M, Christopher-Stine L, Mammen AL, Miller FW. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):86.
2. Uruha A, Goeble HH, Stenzel W. Updates on the Immunopathology in idiopathic inflammatory myopathies. Curr Rheumatol Rep. 2021;23(7):356.
3. Pestronk A. Acquired immune and inflammatory myopathies: pathologic classification. Curr Opin Rheumatol. 2011;23(6):595–604.
4. Malatré S, Bachasson D, Mercy G, Sarkis E, Anquetil C, Benveniste O, Allenbach Y. MRI and muscle imaging for idiopathic inflammatory myopathies. Brain Pathol. 2021;31(3):e12954.
5. Pipitone N. Value of MRI in diagnostics and evaluation of myositis. Curr Opin Rheumatol. 2016;28(6):625–30.
6. Porta F, Radunovic G, Vlad V, Micu MC, Nestorova R, Petranova T, Iagnocco A. The role of Doppler ultrasound in rheumatic diseases. Rheumatology (Oxford). 2012;51(6):976–82.
7. Filippucci E, Cipolletta E, Masahi Mirza R, Carotti M, Giovanaggi A, Salaffi F, Tardella M, Di Matteo A, Di Carlo M. Ultrasound imaging in rheumatoid arthritis. Radiol Med. 2019;124(11):1087–100.
8. Dubois G, Kheireddine W, Vergani C, Bonneau D, Thoreux P, Rouch P, Tanter M, Gennisson JL, Skalli W. Reliable protocol for shear wave elastography of lower limb muscles at rest and during passive stretching. Ultrasound Med Biol. 2015;41(9):2284–91.
9. Paramalingam S, Needham M, Raymond W, Mastaglia F, Lightowler D, Morin N, Counsel P, Keen HI. Muscle shear wave elastography, conventional B mode and power doppler ultrasonography in healthy adults and patients with autoimmune inflammatory myopathies: a pilot cross-sectional study. BMC Musculoskelet Disord. 2021;22(1):57.
10. Bottai M, Tjarnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open. 2017;3(2):e000507.
11. Rose MR. Group BW. 188th ENMC international workshop: inclusion body myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscul Disord. 2013;23(12):1044–55.
12. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, Vencovský J, de Visser M, Hughes RA. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14(5):337–45.
13. Bruce B, Fries JF. The health assessment questionnaire (HAQ). Clin Exp Rheumatol. 2005;23(Suppl 35):9–18.
14. Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient/patient global activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT); Disease Activity Score (DAS). Short Form 36 (SF-36), Child Health Questionnaire (CHQ); physician global damage, Myositis Damage Index (MDI); Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (BBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CADSI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S118–157.
15. Bhansing KJ, van Rosmalen MV, van Engelen BG, van Riel PL, Pillen S, Vronk MC. Muscle ultrasonography is a potential tool for detecting fascitis in dermatomyositis and polymyositis: comment on the article by Yoshida. Arthritis Rheumatol. 2017;69(11):2248–9.
16. Joyce NC, Oksarsson B, Jin LW. Muscle biopsy evaluation in neuromuscular disorders. Phys Med Rehabil Clin N Am. 2012;23(3):609–31.
17. Alfunrah AM, O’Connor P, Tan AL, Hensor EMA, Ladas A, Emery P, Wakefield RJ. Muscle shear wave elastography in idiopathic inflammatory myopathies: a case-control study with MRI correlation. Skeletal Radiol. 2019;48(12):1209–1219.
18. Stecco C, Tiengo C, Stecco A, Porzionato A, Macchi V, Stern R, De Caro R. Fascia redefined: anatomical features and technical relevance in fascial disorders. Phys Med Rehabil Clin N Am. 2012;23(3):609–31.
19. Alfunrah AM, O’Connor P, Tan AL, Hensor EMA, Ladas A, Emery P, Wakefield RJ. Muscle shear wave elastography in idiopathic inflammatory myopathies: a case-control study with MRI correlation. Skeletal Radiol. 2019;48(12):1209–1219.
20. Beckhart JZ, Leerman S, Dubovitz V. Ultrasound imaging in the diagnosis of muscle disease. J Pediatr. 1982;101(5):656–60.
21. Alfunrah AM, O’Connor P, Hensor E, Tan AL, Emery P, Wakefield RJ. The effect of unit, depth, and probe load on the reliability of muscle shear wave elastography: variables affecting reliability of SWE. J Clin Ultrasound. 2018;46(2):108–15.
22. Needham M, Mastaglia FL. Sporadic inclusion body myositis: a review of recent clinical advances and current approaches to diagnosis and treatment. Clin Neurophysiol. 2016;127(3):1764–73.
22. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford). 2009;48(6):607–12.

23. Paramalingam S, Morgan K, Becce F, Diedrichsen LP, Ikeda K, Mandl P, Ohmdorf S, Seddie AD, Sharp V, Tan AL, et al. Conventional ultrasound and elastography as imaging outcome tools in autoimmune myositis: a systematic review by the OMERACT ultrasound group. Semin Arthritis Rheum. 2021;51(3):661–76.

24. Conticini E, Falsetti P, Al Khayyat SG, Baldi C, Bellisai F, Bardelli M, Sota J, Cantarini L, Frediani B. A novel grey Scale and Power Doppler ultrasonographic score for idiopathic inflammatory myopathies: Siena Myositis Ultrasound Grading Scale. Rheumatology (Oxford). 2021;61:185–94.

25. Meng C, Adler R, Peterson M, Kagen L. Combined use of power Doppler and gray-scale sonography: a new technique for the assessment of inflammatory myopathy. J Rheumatol. 2001;28(6):1271–82.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions